Nexstim Oyj: Correction to the Invitation to the Annual General Meeting of Nexstim Plc
Correction to the Invitation to the Annual General Meeting of Nexstim Plc
In accordance with the invitation to the Annual General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) dated 15 April 2021, the shareholders of the Company have been invited to the Annual General Meeting to be held on 11 May 2021 commencing at 12.00 (EEST).
The invitation to the meeting of 15 April 2021 includes a writing error stating that transfers of shares from the Company to the Receiving Shareholders required for the final adjustments of their number of shares (after reduction) are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Sweden and 19th May 2021 in Finland. Notwithstanding the above-mentioned, the transfers of shares are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Finland and 19th May 20
Investegate |CoinShares International Limit Announcements | CoinShares International Limit: CoinShares and 3iQ have collaborated to launch the 3iQ CoinShares Ether Exchange Traded Fund ( ETF )
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
– LIDDS publishes Annual Report for 2020
The Annual Report is attached to this press release and alos available on LIDDS website: https://liddspharma.com/investors/#financial-reports.
For more information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 [email protected]
LIDDS AB is required to disclose this information pursuant to
Nasdaq First North Growth Market – Rulebook
. The information was submitted for publication, through the agency of the aforementioned contact person, on April 16, 2021 at 15:00 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical ph
(0)
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST)
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT Systems to Treat MDD
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that the company s SmartFocus nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression.
Oladele Adebogun M.D. said, I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the num
vimarsana © 2020. All Rights Reserved.